Research for COVID-19 vaccine among lung cancer patients undergoing chemotherapy
- Conditions
- COVID-19
- Registration Number
- JPRN-jRCT1071210024
- Lead Sponsor
- akashima Kei
- Brief Summary
BNT162b2 vaccination in lung cancer patients undergoing anticancer treatment significantly increased antibody titers and showed acceptable safety. Immunogenicity in these patients could be inadequate compared with that in non-cancer patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 93
1) Any of the following a or b
a Patients with lung cancer on chemotherapy over 50 years
b Patients with underlying disease (except for cancer) over 50 years old
2) Those who are visiting a medical institution conducting research (Kameda Medical Center, Chikamori hospital)
3) Subjects who voluntarily recieve the COVID-19 vaccine
4) Written informed consent
1) Those who have the contraindications for vaccination
2) Those who have been vaccinated with the new coronavirus vaccine in the past
(Including participation in clinical trials or clinical trials / research)
3) Those who are receiving systemic steroids / immunosuppressants (excluding administration of anticancer drugs as antiemetics)
4) Persons with autoimmune disease under treatment
5) Those who have experienced an acute illness that requires antibiotics or steroids within the past one month
6) Those who have a fever at the time of vaccination, those who present with acute serious illness
7) Persons who are judged by the principal investigator or the investigator to be inappropriate as research subjects
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method immunogenicity
- Secondary Outcome Measures
Name Time Method effectiveness, side efects after vaccination, vaccine associated adverse events